WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Roche

RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

www.roche.com.

Roche RSS Channel

Filters
List of articles in category Roche
Title Published Date
Roche and Polyphor join efforts to combat multi-drug-resistant bacterial infections 04 November 2013
Roche posts strong sales growth in the first nine months of 2013 17 October 2013
Roche inaugurates Translational and Clinical Research Center at the Alexandria Center for Life Science in New York City 09 October 2013
Christoph Franz nominated to become new Roche Chairman 16 September 2013
Roche halts investigation of aleglitazar 10 July 2013
Roche Group posts strong sales growth in the first quarter 11 April 2013
Roche launches new process for accessing clinical trial data 26 February 2013
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer 24 February 2013
Roche delivers strong 2012 results 31 January 2013
Roche reports positive studies of MabThera given by subcutaneous injection 10 December 2012
Roche and the Innovative Medicines Initiative join forces to promote use of Nobel Prize-winning stem cell technology 06 December 2012
Results from the positive phase III AVAglio study 18 November 2012
Roche Group posts strong sales growth in the third quarter 16 October 2012
Roche leads healthcare sector in key sustainability index for fourth consecutive year 13 September 2012
Roche committed to innovation and growth 06 September 2012
Roche and Lucerne Festival renew partnership and launch new project for young composers 23 August 2012
FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema 20 August 2012
The Phase III AVAglio study met its co-primary endpoint 13 August 2012
Roche reports second positive study of RoACTEMRA 29 July 2012
Roche to streamline research and development activities 26 June 2012
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19
  • Scientists develop new biomimetic formulation for treating glioblastoma
  • SARS-CoV-2 hijacks nanotubes between neurons to infect them

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Roche
  4. Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.